In ALK‐positive NSCLC with CNS metastases, Binghao Zhao et al.34believed that for BM patients in PFS, lorlatinib showed the strongest benefit, but ORR differences were not obvious between third‐ and second‐generation inhibitors. This evidence concerns the gene ALK and non-small cell lung carcinoma.